Molecular Determinants of Outcomes With Pembrolizumab vs Paclitaxel in Patients With Gastroesophageal Adenocarcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Annals of Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Molecular Determinants of Clinical Outcomes With Pembrolizumab Versus Paclitaxel in a Randomized, Open-Label, Phase III Trial in Patients With Gastroesophageal Adenocarcinoma
Ann. Oncol 2021 Sep 01;32(9)1127-1136, K Shitara, M Özgüroğlu, YJ Bang, M Di Bartolomeo, M Mandalà, MH Ryu, C Caglevic, HC Chung, K Muro, E Van Cutsem, J Kobie, R Cristescu, D Aurora-Garg, J Lu, CS Shih, D Adelberg, ZA Cao, CS FuchsFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.